Wide Ranks

CRBP

Corbus Pharmaceuticals Holdings

17.64

Top Statistics
Market Cap 214 M Forward PE -3.22 Revenue Growth 0.00 %
Current Ratio 13.84 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -1.29 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 159 M Total Cash Per Share 13.08 Total Debt 3 M
Total Debt To Equity 2.40 Current Ratio 13.84 Book Value Per Share 12.36
All Measures
Short Ratio 646.00 % Message Board Id finmb_254045988 Fax 617 663 6085
Shares Short Prior Month 2 M Return On Equity -0.5132 City Norwood
Uuid 3b397f81-5586-3f39-a5d2-f2fadc51d52c Previous Close 17.98 First Trade Date Epoch Utc 1 B
Book Value 12.36 Beta 2.56 Total Debt 3 M
Volume 153457 Price To Book 1.43 Last Split Date 1 B
Fifty Two Week Low 4.75 Total Cash Per Share 13.08 Shares Short Previous Month Date 1 B
Target Median Price 62.50 Max Age 86400 Recommendation Mean 1.25
Sand P52 Week Change 0.3133 Target Mean Price 59.50 Net Income To Common -38700316
Short Percent Of Float 0.2370 Implied Shares Outstanding 12 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 240900 Average Volume10days 240900
Total Cash 159 M Next Fiscal Year End 1 B Held Percent Insiders 0.0075
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 17.98 Target Low Price 40.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 18.91 Open 17.93 Free Cashflow -25396628
State MA Dividend Yield 0.00 % Return On Assets -0.2882
Time Zone Short Name EST Trailing Eps -4.71 Day Low 17.54
Address1 500 River Ridge Drive Shares Outstanding 12 M Price Hint 2
Target High Price 75.00 Website https://www.corbuspharma.com 52 Week Change 1.64
Average Volume 659803 Forward Eps -5.24 Recommendation Key strong_buy
Compensation As Of Epoch Date 1 B Quick Ratio 1370.90 % Last Split Factor 1:30
Regular Market Day High 18.15 Is_sp_500 False Profit Margins 0.00 %
Debt To Equity 2.40 Fifty Two Week High 61.90 Day High 18.15
Shares Short 2 M Regular Market Open 17.93 Industry Key biotechnology
Earnings Growth 0.00 % Revenue Growth 0.00 % Shares Percent Shares Out 0.1972
Operating Cashflow -36860472 Currency USD Time Zone Full Name America/New_York
Market Cap 214 M Is_nasdaq_100 False Zip 02062
Quote Type EQUITY Industry Biotechnology Long Name Corbus Pharmaceuticals Holdings, Inc.
Regular Market Day Low 17.54 Held Percent Institutions 1.05 Current Price 17.64
Enterprise To Ebitda -1.29 Financial Currency USD Current Ratio 13.84
Industry Disp Biotechnology Number Of Analyst Opinions 8 Country United States
Float Shares 8 M Two Hundred Day Average 38.74 Enterprise Value 59 M
Forward PE -3.22 Regular Market Volume 153457 Ebitda -45617700
Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness.

It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.

It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings.

The company was incorporated in 2009 and is based in Norwood, Massachusetts.